Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Consolidated statements of comprehensive income

v3.22.0.1
Consolidated statements of comprehensive income - USD ($)
12 Months Ended
Feb. 28, 2021
Feb. 29, 2020
Feb. 28, 2019
Statement Of Comprehensive Income [Abstract]      
Revenue $ 55,473,725 $ 16,898,178  
Costs and expenses:      
Cost of revenue (4,167,967) (103,631)  
Research and development (189,029) (9,172) $ (853,677)
Marketing and sales (4,342,591) (21,241) (42,453)
General and administrative (14,382,806) (1,406,087) (1,133,296)
Impairment - trade receivables (3,925,335) (183,232)  
Impairment - intangible assets (1,907,503)    
Impairment - contract costs (1,100,000)    
Total costs and expenses (30,015,231) (1,723,363) (2,029,426)
Results from operating activities 25,458,494 15,174,815 (2,029,426)
Other income 113,456    
Change in fair value of warrant liabilities (26,111,685)    
Finance income 48,011 1,342 607
Finance costs (130,490) (2,817) (9,256)
Net finance costs (82,479) (1,475) (8,649)
Profit/(Loss) before income tax 51,601,156 15,173,340 (2,038,075)
Tax expense (6,348,444) (1,592,549)  
Total comprehensive income/ (loss), representing net profit/(loss) for the year $ 45,252,712 $ 13,580,791 $ (2,038,075)
Earnings per share      
Basic and diluted $ 0.74 $ 4.07 $ (20,381.00)